Dr. Lestini became CEO of Pyramid Biosciences in January 2022, after previously serving as the Company’s Chief Medical Officer. He joined the Company from Bristol-Myers Squibb, where he most recently was Vice President and Development Leader for the relatlimab (anti-LAG3) immunotherapy program. In this capacity, Dr. Lestini oversaw the development and commercialization strategy for this novel immunotherapy agent across a wide range of tumors. Dr. Lestini brings over a decade of early-stage and late-stage development leadership experience in Oncology, including the design, execution and submissions leading to the first global approvals of OPDIVO (nivolumab, anti-PD1) and OPDUALAG (nivolumab plus relatlimab). Previously, Dr. Lestini served as the Global Medical Affairs Head and Development Leader for three hematology products, OPDIVO, SPRYCEL (dasatinib), and EMPLICITI (elotuzumab). Prior to joining BMS, he led the early-stage clinical development for the BRAF inhibitor program at Hoffmann-La Roche. Dr. Lestini is a Board-Certified Pediatric Hematologist-Oncologist, and received his MD and PhD degrees from Case Western Reserve University, and completed his fellowship training at the Children’s Hospital of Philadelphia (CHOP).